Amplifica is a preclinical stage biopharmaceutical company focused on developing novel treatments to address androgenic alopecia.
Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. Its main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year, or 31% of all global deaths according to the World Health Organization. It was founded in 2017 and is headquartered in New Hope, Pennsylvania.
Psudo manufactures sneakers that are locally sourced and built with recycled materials. It also provides antimicrobial, anatomically foot support for all-day wear, enabling customers to get a range of sustainable footwear. The company was founded in 2021 and is based in Saint Louis, Missouri.
Outstanding Foods is a plant-based foods company that specializes in the fields of consumer goods, beverages, and snack foods. Their products contain pure, wholesome ingredients combined with proprietary chef-crafted methods. It was founded in 2016 and headquartered in Venice, California.
Aerami Therapeutics focuses on developing novel inhaled therapies for the treatment of chronic diseases. It features a proprietary, smart, handheld soft mist device that allows convenient and confident delivery of insulin into a patient's lungs in just a few breaths yielding high lung deposition and distribution. It was founded in 2010 and headquartered in Durham, North Carolina.
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer evaluation, given that the majority of Americans report never having been checked for skin cancer. The DermaSensor device is an affordable, handheld tool that uses machine learning and spectroscopy to objectively evaluate skin lesions for potential cancer in seconds.
Viscient Biosciences is a biotechnology company working at the intersection of human 3D tissue technology and multi-omics (genomics, transcriptomics, metabolomics) analysis to develop drugs across a range of therapeutic areas, with an initial focus in non-alcoholic steatohepatitis (NASH,“fatty liver disease”). Founded and staffed by a team composed of former Organovo and Ardea Biosciences scientists and entrepreneurs, Viscient is driving a revolution in drug discovery, overthrowing the old paradigm of discovery in animal models.
Zoomcar is the marketplace for car sharing in emerging markets, with over 20,000 cars on its technology-driven platform across India, Southeast Asia, and Egypt. Zoomcar empowers host entrepreneurs to safely and easily share their cars to earn additional passive income. Guests in the Zoomcar community enjoy a diverse, affordable selection of cars to unlock memorable driving experiences with friends and family. Founded in 2013 and headquartered in Bengaluru, India, Zoomcar employs over 300 people and operates in 50 cities across India, Indonesia, Vietnam, and Egypt. Uri Levine, the co-founder of mobility unicorns Waze and Moovit, currently serves as Zoomcar’s Chairman of the Board.
Hydrobuilder.com offers a large selection of indoor grow lights, complete hydroponic system, plant nutrients, ventilation systems, grow tents and more! Hydrobuilder supplies both hobby and commercial cultivators in all 50 states.
Zoomcar is the marketplace for car sharing in emerging markets, with over 20,000 cars on its technology-driven platform across India, Southeast Asia, and Egypt. Zoomcar empowers host entrepreneurs to safely and easily share their cars to earn additional passive income. Guests in the Zoomcar community enjoy a diverse, affordable selection of cars to unlock memorable driving experiences with friends and family. Founded in 2013 and headquartered in Bengaluru, India, Zoomcar employs over 300 people and operates in 50 cities across India, Indonesia, Vietnam, and Egypt. Uri Levine, the co-founder of mobility unicorns Waze and Moovit, currently serves as Zoomcar’s Chairman of the Board.
Outstanding Foods is a plant-based foods company that specializes in the fields of consumer goods, beverages, and snack foods. Their products contain pure, wholesome ingredients combined with proprietary chef-crafted methods. It was founded in 2016 and headquartered in Venice, California.
DarioHealth is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue.
Kintara Pharmaceuticals, Inc. engages in developing and commercializing cancer therapies in orphan and other cancer indications for the treatment of patients failing modern targeted or biologic therapy. The company’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. Kintara Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. The company was founded in 2010 and is headquartered in Vancouver, Canada.
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer evaluation, given that the majority of Americans report never having been checked for skin cancer. The DermaSensor device is an affordable, handheld tool that uses machine learning and spectroscopy to objectively evaluate skin lesions for potential cancer in seconds.
Outstanding Foods is a plant-based foods company that specializes in the fields of consumer goods, beverages, and snack foods. Their products contain pure, wholesome ingredients combined with proprietary chef-crafted methods. It was founded in 2016 and headquartered in Venice, California.
Aerami Therapeutics focuses on developing novel inhaled therapies for the treatment of chronic diseases. It features a proprietary, smart, handheld soft mist device that allows convenient and confident delivery of insulin into a patient's lungs in just a few breaths yielding high lung deposition and distribution. It was founded in 2010 and headquartered in Durham, North Carolina.
DarioHealth Corp. is a digital health company that specializes in developing and commercializing proprietary technology for laboratory testing via smartphones and mobile devices. Its flagship product, the Dario Smart Diabetes Management Solution, integrates a cloud-based software application with a compact blood glucose monitoring device. This solution enables users to manage their diabetes through real-time data tracking, coaching, and support, while also providing alerts and analysis of health trends. DarioHealth markets its products directly to consumers and through retail pharmacies, hospitals, and online channels. The company also offers a digital platform, DarioEngage, to enhance user engagement and support in managing chronic illnesses. Founded in 2011 and headquartered in Caesarea, Israel, DarioHealth emphasizes personalized, evidence-based interventions driven by data analytics and individual coaching, addressing various health concerns such as diabetes, hypertension, and weight management.
Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. Its main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year, or 31% of all global deaths according to the World Health Organization. It was founded in 2017 and is headquartered in New Hope, Pennsylvania.
Hydrofarm is a distributor and manufacturer of controlled environment agriculture equipment and supplies, including high-intensity grow lights, climate control solutions, and growing media, as well as a broad portfolio of innovative and proprietary branded products. The company’s mission is to empower growers, farmers, and cultivators with products that enable greater quality, efficiency, consistency, and speed in their growing projects. For more than 40 years, Hydrofarm has helped growers in the U.S. and Canadian markets make growing easier and more productive.
Orchestra BioMed, Inc. is a biomedical innovation company focused on developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions. Its main focus is on developing new therapies for cardiovascular diseases which are the leading cause of death worldwide, taking the lives of 17.7 million people each year, or 31% of all global deaths according to the World Health Organization. It was founded in 2017 and is headquartered in New Hope, Pennsylvania.
Aerami Therapeutics focuses on developing novel inhaled therapies for the treatment of chronic diseases. It features a proprietary, smart, handheld soft mist device that allows convenient and confident delivery of insulin into a patient's lungs in just a few breaths yielding high lung deposition and distribution. It was founded in 2010 and headquartered in Durham, North Carolina.
BackBeat Medical Inc. is a medical technology company founded in 2010 to develop novel cardiac stimulation-based therapies for hypertension and heart failure. BackBeat has developed a patented cardiac pacing-based treatment for hypertension (HTN) called programmable hypertension control (PHC) therapy. PHC is comprised of proprietary pacing algorithms that can be readily incorporated into standard pacemakers using standard leads and standard lead placement and thus has broad applicability. PHC offers a new potent device-based HTN therapeutic alternative potentially opening up a large market to treat HTN patients, particularly HTN patients who already have or require a pacemaker. Clinical results generated to date using BackBeat’s own Moderato™ pacemaker incorporating PHC algorithms demonstrate that this therapy has a substantial and sustained therapeutic effect on blood pressure as determined by both in-office cuff measurements (average reduction of 24 mmHg from baseline) and 24-hour ambulatory measurements (average reduction of 14 mmHg from Baseline) with clinical follow up extending past two years in certain patients. BackBeat's PHC therapy is protected by an extensive global patent portfolio.
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero's existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
Caliber Therapeutics, Inc. engages in the development and commercialization of minimally-invasive balloon-based drug delivery products for the intervention of atherosclerotic diseases. It offers Targeted Angioplasty Drug Delivery balloon, a stent-free delivery platform of anti-restenotic drugs, which enables controlled and targeted drug delivery, reduces thrombosis risk, and reduces the need to implant permanent devices.
Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The Company is focused on the development and commercialization of the Pure-Vu® System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
Helocyte Inc. (“Helocyte”), a portfolio company of Fortress Biotech, is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cytomegalovirus (“CMV”). We aim to: (1) secure rights to new technologies via acquisition, licensing, co-development and/or other partnering; (2) fund research and development of new technologies; and (3) ultimately introduce new technologies to market. We are currently progressing three immunotherapies developed in the laboratory of Donald J. Diamond Ph.D., Chair of the Department of Experimental Therapeutics at City of Hope of Duarte, California (“City of Hope”). In March of 2015, Helocyte consummated an exclusive worldwide license and option agreement with City of Hope, acquiring rights to the current Helocyte programs. PepVax, is an HLA-restricted single antigen [UL83 (pp65)] peptide vaccine for controlling CMV in allogeneic hematopoietic stem cell transplant (“HSCT”) recipients. In July of 2015, we opened a Phase 2 study of PepVax in allogeneic HSCT recipients. Our second program, Triplex, is a universal (non-HLA-restricted) recombinant viral vector vaccine expressing three immuno-dominant proteins [UL83 (pp65), UL123 (IE1), UL122 (IE2)] linked to CMV in the post-transplant setting. In November of 2015, we opened a Phase 2 study of Triplex in allogeneic HSCT recipients. We additionally plan to study Triplex in recipients of allogeneic Solid Organ Transplantation. Our third program, Pentamer, is a universal (non-HLA-restricted) recombinant viral vector vaccine expressing five primary subunits of CMV (gH/gL/UL128/UL130/UL131A) linked to viral transmission in utero. The Pentamer program is currently undergoing nonclinical development and will ultimately be studied for prevention of congenital CMV.
Adgero Biopharmaceuticals Holdings, Inc. is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast cancer ("CMBC") who have failed radiation therapy. Use of Adgero's existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.
Kintara Pharmaceuticals, Inc. engages in developing and commercializing cancer therapies in orphan and other cancer indications for the treatment of patients failing modern targeted or biologic therapy. The company’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. Kintara Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. The company was founded in 2010 and is headquartered in Vancouver, Canada.
Aerami Therapeutics focuses on developing novel inhaled therapies for the treatment of chronic diseases. It features a proprietary, smart, handheld soft mist device that allows convenient and confident delivery of insulin into a patient's lungs in just a few breaths yielding high lung deposition and distribution. It was founded in 2010 and headquartered in Durham, North Carolina.
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus is also developing a pipeline of drug candidates from more than 600 novel compounds targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist. Potential indications for CRB-4001 include NASH, among others. Corbus plans to start a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (NIH)-funded proof-of-concept Phase 2 study.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid crystal drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an oral formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia; and MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
DarioHealth Corp. is a digital health company that specializes in developing and commercializing proprietary technology for laboratory testing via smartphones and mobile devices. Its flagship product, the Dario Smart Diabetes Management Solution, integrates a cloud-based software application with a compact blood glucose monitoring device. This solution enables users to manage their diabetes through real-time data tracking, coaching, and support, while also providing alerts and analysis of health trends. DarioHealth markets its products directly to consumers and through retail pharmacies, hospitals, and online channels. The company also offers a digital platform, DarioEngage, to enhance user engagement and support in managing chronic illnesses. Founded in 2011 and headquartered in Caesarea, Israel, DarioHealth emphasizes personalized, evidence-based interventions driven by data analytics and individual coaching, addressing various health concerns such as diabetes, hypertension, and weight management.
Armada Water Assets provides water supply, collection, and remediation services. Armada is a fully integrated service company dedicated to the safe and cost-effective collection, handling, transport, treatment, and reuse of contaminated water produced by conventional oil and gas production (produced water) and hydraulic-fracturing flow-back water. It was founded in 2012 and headquartered in Houston, Texas.
Deem is a technology platform for the business travel industry focusing on travel, car service, and expense solutions. Its mission is to make business travel less complicated for travelers, less costly for employers, and more profitable for service providers.
GlobeImmune, operates as a biopharmaceutical company. It engages in developing and manufacturing Tarmogens, a targeted molecular immunotherapy for the treatment of cancer and infectious diseases. Its products include GI-3000, a Tarmogen for epidermal growth factor receptor over expressing tumors; GI-4000, a Tarmogen for mutated-Ras mediated cancers; GI-5005, a Tarmogen for chronic hepatitis C infection; GI-8000, a Tarmogen for influenza; and GI-10000 Targeted Ablation of Mutational Escape, a novel use of the Tarmogen platform that eliminates or prevents the emergence of mutated escape variants in patients receiving antiviral or targeted cancer therapies. GlobeImmune was founded in 1995 as Ceres Pharmaceuticals, Inc. The company is based in Louisville, Colorado.
Organovo is focused on delivering breakthrough three-dimensional biology capabilities to create tissue on demand for research and surgical applications. As the first company with a three-dimensional tissue technology that works across tissue types, they are meeting the promise of regenerative medicine to fill unmet medical needs.
InVivo Therapeutics Corporation is a medical device company focused on utilizing polymers as a platform technology to develop treatments to restore function in individuals paralyzed as a result of traumatic spinal cord injuries. The company was founded in 2005 on the basis of research initiated in Cambridge, Massachusetts, United States.
PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity. PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.
Psudo manufactures sneakers that are locally sourced and built with recycled materials. It also provides antimicrobial, anatomically foot support for all-day wear, enabling customers to get a range of sustainable footwear. The company was founded in 2021 and is based in Saint Louis, Missouri.